AI assistant
AstraZeneca PLC — Remuneration Information 2014
Mar 31, 2014
5229_dirs_2014-03-31_393c1d8b-f4ca-4b1a-98f9-9a5ac5889357.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 5981D
AstraZeneca PLC
31 March 2014
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 28 March 2014, Dr Briggs Morrison, EVP, Global Medicines Development & Chief Medical Officer, a person discharging managerial responsibilities, was granted awards under the terms of the AstraZeneca Investment Plan (AZIP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Deferred Bonus Plan (AZDBP) over the Company's American Depositary Shares (ADSs) as detailed below. One ADS equals one ordinary share.
| Name | Shares awarded under AZIP | Shares awarded under AZPSP | Shares awarded under AZDBP | Award price per share |
| Briggs Morrison | 4,004 | 24,025 | 2,173 | $64.68 |
The AZIP award is subject to a four-year performance period (1 January 2014 to 31 December 2017) and a subsequent four-year holding period (1 January 2018 to 31 December 2021).
The AZPSP award is subject to a three-year performance period (1 January 2014 to 31 December 2016).
The AZDBP award is subject to a three-year holding period (28 March 2014 to 27 March 2017).
A summary of these plans and information about the performance measures that relate to the AZIP and AZPSP awards is set out in the Directors' Remuneration Report in the AstraZeneca Annual Report and Form 20-F Information 2013 which is available on the Company's website www.astrazeneca.com.
A C N Kemp
Company Secretary
31 March 2014
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSUARURSAAOOAR